The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients
- Author(s): Paff, M
- Alexandru-Abrams, D
- Hsu, FPK
- Bota, DA
- et al.
Published Web Locationhttps://doi.org/10.4161/21645515.2014.983002
© 2014 Taylor & Francis Group, LLC. Glioblastoma Multiforme (GBM) is the most common type of brain tumor and it is uniformly fatal. The community standard of treatment for this disease is gross or subtotal resection of the tumor, followed by radiation and temozolomide. At recurrence bevacizumab can be added for increased progression free survival. Many challenges are encountered while trying to devise new drugs to treat GBM, such as the presence of the blood brain barrier which is impermeable to most drugs. Therefore in the past few years attention was turned to immunological means for the treatment of this devastating disease. EGFRvIII targeting has proven a good way to attack glioblastoma cells by using the immune system. Although in still in development, this approach holds the promise as a great first step toward immune-tailored drugs for the treatment of brain cancers.
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.